Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ: TLSA )

0.8199 -0.0801 (-8.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 497,445
Open 0.9000
Bid (Size) 0.8001 (15)
Ask (Size) 0.9061 (10)
Prev. Close 0.9000
Today's Range 0.8100 - 0.9050
52wk Range 0.4100 - 1.740
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Performance

YTD
+20.43%
+20.43%
1 Month
-7.36%
-7.36%
3 Month
-14.58%
-14.58%
6 Month
-33.34%
-33.34%
1 Year
+63.91%
+63.91%

More News

Read More
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Neurology-Focused Tiziana Life Confirms Discovery In Multiple Sclerosis Therapy Study
Via Benzinga
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Tiziana Life Sciences Announces First Patient with Moderate Alzheimer’s Disease Dosed with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Elon Musk Says Amazon Founder Jeff Bezos Urged Tesla, SpaceX Investors To Dump Stakes, Predicting Trump's Loss
Via Benzinga
Topics Government
Exposures Political
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Cathie Wood Redirects Elon Musk's DOGE Focus Toward Nuclear Energy Amid Regulatory Challenges: Here's How Oklo, Cameco, Centrus Energy And Other Stocks Performed
Via Benzinga
Topics ETFs Energy
Exposures Fossil Fuels
Donald Trump Gives Tesla Wings For 27% Rally Since Presidential Election
Via Investor's Business Daily
Topics Government
Exposures Political
Tesla Reclaims $1 Trillion Market Cap For First Time Since 2022 In Huge Trump Run
Via Investor's Business Daily
Topics Government
Exposures Political
Tesla Surges To 15-Month High On Election; Musk-Trump Alliance In Focus
Via Investor's Business Daily
Cathie Wood Sells Tesla Before Election; Musk Cabinet Position "Not What Shareholders Want To See"
Via Investor's Business Daily
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.